Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice

Exclusion Criteria

• •Medical or psychiatric incapacity to provide informed consent.
• •Known hypersensitivity to trastuzumab or pertuzumab.
• •Current treatment with an investigational drug.
• •Participation in a clinical trial that involves adding an investigational drug to the standard neoadjuvant clinical treatment with chemotherapy, pertuzumab, and the trastuzumab biosimilar CT-P6 (Herzuma®).
• •Withdrawal of consent to participate in the study. The patient may withdraw their consent at any time without having to justify their decision and without any detriment to their clinical care.
• •Patient who does not wish to receive or is not a candidate for oncological treatment with chemotherapy or dual anti-Her2 blockade.
• •Patient diagnosed with another prognostically relevant neoplastic disease in the previous two years. The exceptions are carcinoma in situ of the cervix or breast, and basal cell or squamous cell carcinoma of the skin.
• •Non-neoplastic disease with a prognosis of less than 1 year.
• •Medical condition or patient characteristics that, in the investigator's judgment, pose a high risk of serious complications during treatment.
• •Being pregnant or breastfeeding.
• •Inability to cooperate and comply with the study protocol.